TABLE 2

SPRINT results at a glance

Outcome	Percent per year		Hazard ratio
Outcome	Intensive therapy	Standard therapy	Hazard ratio
Primary outcome^a	1.65	2.19	0.75^b
Secomdary outcomes
Myocardial infarction	0.65	0.78	0.83
Other acute coronary syndromes	0.27	0.27	1.00
Stroke	0.41	0.47	0.89
Heart failure	0.41	0.67	0.62^b
Cardiovascular mortality	0.25	0.43	0.57^b
Other secondary outcomes
All-cause mortality	1.03	1.40	0.73^b
In patients with chronic kidney disease—decrease in eGFR of ≥ 50% or end-stage renal disease	0.33	0.36	0.89
In patients without chronic kidney disease—decrease in eGFR of ≥ 30% to < 60 mL/min/1.73 m²	1.21	0.35	3.49^b

Adverse events	Percent of patients		Hazard ratio
Adverse events	Intensive therapy	Standard therapy	Hazard ratio
Hypotension	3.4	2.0	1.70^b
Syncope	3.5	2.4	1.44^b
Hyponatremia	3.8	2.1	1.76^b
Hypokalemia	2.4	1.6	1.50^b
Injurious fall	7.1	7.1	1.00
Orthostatic hypotension without dizziness	16.6	18.3	0.88^b
Orthostatic hypotension with dizziness	1.3	1.5	0.85
Acute kidney injury	4.4	2.6	1.71^b

↵a The composite of myocardial infarction, acute coronary syndrome, stroke, heart failure, or death from cardiovascular causes.
↵b P<.05.
eGFR = estimated glomerular filtration rate, according to the Modification of Diet in Renal Disease study equation.
Information from SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373:2103-21 16.